Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but subsequently die of relapse 1 that is driven by chemotherapy-resistant leukaemic stem cells (LSCs) The immunoreceptor NKG2D is expressed by cytotoxic lymphocytes and recognizes stress-induced ligands of the MIC and ULBP families on target cells 8, 9 
. However, this precludes analyses of their interaction with lymphocytes as components of anti-tumour immunity 5 , which LSCs must escape to induce cancer. Here we demonstrate that stemness and immune evasion are closely intertwined in AML. Using xenografts of human AML as well as syngeneic mouse models of leukaemia, we show that ligands of the danger detector NKG2D-a critical mediator of anti-tumour immunity by cytotoxic lymphocytes, such as NK cells [6] [7] [8] [9] -are generally expressed on bulk AML cells but not on LSCs. AML cells with LSC properties can be isolated by their lack of expression of NKG2D ligands (NKG2DLs) in both CD34-expressing and non-CD34-expressing cases of AML. AML cells that express NKG2DLs are cleared by NK cells, whereas NKG2DL-negative leukaemic cells isolated from the same individual escape cell killing by NK cells. These NKG2DL-negative AML cells show an immature morphology, display molecular and functional stemness characteristics, and can initiate serially re-transplantable leukaemia and survive chemotherapy in patient-derived xenotransplant models. Mechanistically, poly-ADP-ribose polymerase 1 (PARP1) represses expression of NKG2DLs. Genetic or pharmacologic inhibition of PARP1 induces NKG2DLs on the LSC surface but not on healthy or pre-leukaemic cells. Treatment with PARP1 inhibitors, followed by transfer of polyclonal NK cells, suppresses leukaemogenesis in patient-derived xenotransplant models. In summary, our data link the LSC concept to immune escape and provide a strong rationale for targeting therapy-resistant LSCs by PARP1 inhibition, which renders them amenable to control by NK cells in vivo.
The immunoreceptor NKG2D is expressed by cytotoxic lymphocytes and recognizes stress-induced ligands of the MIC and ULBP families on target cells 8, 9 . We screened 177 patients with AML (Supplementary Table 1 ) for expression of individual NKG2DLs (MICA, MICB, ULBP1 and ULBP2, ULBP5 or ULBP6), and by using a NKG2D-Fc chimeric protein to simultaneously study these and-potentially-as yet unknown NKG2DLs. Beyond the reported variation in patterns of expression of NKG2DLs among cases of AML 10 , we also detected considerable heterogeneity in AML cells derived from individual patients (Fig. 1a, b, Extended Data Fig. 1a) . Comparison of intrapatient NKG2DL
+ and NKG2DL − subpopulations of AML cells revealed that NKG2DL
− AML cells are smaller, with less granularity and lower cell-to-nucleus size ratio ( (Fig. 1j ). NKG2D-Fc staining did not bias these results (Extended Data Fig. 2e-g ). Notably, NKG2DL
− cells generated both NKG2DL − and NKG2DL + progeny in engrafted mice (Fig. 1k, l) , but the latter progeny remained non-leukaemogenic (Extended Data Fig. 2b, c) . The ability of NKG2DL + AML cells to home to the bone marrow was reduced tenfold (0.001 ± 0.002% versus 0.01 ± 0.009% human leukaemic among mouse bone marrow cells; Fig. 1m ) and these cells also did not engraft after direct injection into the bone marrow (Extended Data Fig. 2d , Supplementary Table 2) .
In mice engrafted with AML cells, in vivo treatment with cytarabine reduced infiltration of the bone marrow by NKG2DL + , but not NKG2DL − , AML cells (Fig. 1n, o) , which indicates that the latter are more resistant to chemotherapy. Consistently, higher proportions of NKG2DL
+ cells in patients with AML associated with favourable molecular risk, better response to induction chemotherapy and improved overall survival (Fig. 1p, Extended Data Fig. 3 ). Molecular expression analyses revealed enrichment of the established LSC, haematopoietic stem cell and 17-gene stemness signatures (see Methods) in NKG2DL
− cells. By contrast, the common lineage-committed progenitor signature was enriched in corresponding NKG2DL
+ fractions (Fig. 1q, Extended Data Fig. 1e ). Notably, this was not due to differences in leukaemia-specific genetic aberrations in NKG2DL
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In mice, healthy bone marrow cells lacked expression of NKG2DLs, and pre-leukaemic Dnmt3a or Tet2 mutations were insufficient to induce expression of NKG2DLs (Extended Data Fig. 4a, b) . However, the Mll-Enl (Mll is also known as Kmt2a; Enl is also known as Mllt1) and Mll-ptd/Flt3-ITD mouse models of leukaemia (see Methods) contained both NKG2DL
− and NKG2DL + subpopulations of leukaemic cells (Extended Data Fig. 4a, b) ; in these models, increased colony-forming activity and selective capacity for the induction of leukaemia in vivo were again confined to NKG2DL − cells (Extended Data Fig. 4d-n) , despite the fact that both subpopulations express the genetic leukaemic driver (Extended Data Fig. 4c ). In vivo depletion experiments of NK cells confirmed that the NKG2DL + subpopulations are non-leukaemogenic even in the absence of surveillance by NK cells (Extended Data Fig. 5 ).
Co-cultivation of bulk AML cells with polyclonal NK cells (pNKCs) preferentially reduced NKG2DL
+ cells, and thereby enriched for NKG2DL − leukaemic cells (Fig. 2a-c , Extended Data Fig. 6a ). Notably, this effect was abrogated by NKG2D blockade (Fig. 2b , c;7 ± 3% versus 82 ± 9% NKG2DL + cells, compared to pre-culture conditions). Non-LSCs were preferentially recognized by pNKCs and triggered the respective effector functions of the NK cells (Extended Data Fig. 6b-d) . Consistently, in vitro co-culture with pNKCs alone, or pNKCs pretreated with isotype control (mock), enriched for AML cells with increased clonogenicity, as compared to control cultures without DNMT3A  NPM1  FLT3  NRAS  WT1  TP53  IDH1  RUNX1  ASXL1  KIT  WT1  WT1  NPM1  NRAS  NRAS  NRAS  NPM1  NRAS  NRAS  IDH1  IDH2  FLT3  FLT3  FLT3  FLT3  FLT3  FLT3  DNMT3A  DNMT3A  NPM1  WT1 + subpopulations of AML cells are sorted from the same patients, and analysed side-by-side using equal cell numbers. b, Representative examples of the gating strategy. c, Representative examples of forward and sideward scatter plots. d, Representative examples of May-Grünwald-Giemsa staining. e, f, Quantification of cell-to-nucleus size ratio (e) (n = 50 cells quantified for each subpopulation, n = 5 cases of AML; boxes represent median and 25th-75th percentiles, whiskers are minimum to maximum) and in vitro colony formation (f) (means of technical triplicates, n = 38 cases of AML). g-i, Long-term engraftment in NSG mice. Flow cytometry of mouse bone marrow (BM) (g; n = 18 cases of AML), and peripheral blood (PB) and organs (h; n = 10 cases of AML). Each dot represents one mouse. i, Representative bone marrow histopathology images. Left, haematoxylin and eosin (H&E); right, anti-CD33, 630× magnification, n = 5 cases of AML, n = 3 mice per group). j, Kaplan − and NKG2DL + AML cells from engrafted mice (post-transplantation) compared to corresponding patient-derived samples (pre-transplantation). Representative plots (k) and summarized results (l) (no. 1, 7 and 8, n = 3; no. 6, n = 4 mice per subpopulation). m, Percentage of CFSE-labelled human CD33
+ AML cells that home to the bone marrow (each dot represents 1 mouse, n = 3 mice per subpopulation, n = 3 cases of AML). n, o, Mice engrafted with AML cells were treated with cytarabine (1 mg subcutaneously daily, for 2 to 4 days), and percentages of NKG2DL − and NKG2DL + AML cells analysed in the mouse bone marrow before and after treatment. n, Exemplary results. o, n = 8 cases of AML. Connected dots depict percentages of NKG2DL − (left) and NKG2DL + (right) AML cells before and after treatment in one mouse. p, Correlation of surface expression of NKG2DLs and overall survival in patients with AML (≤65 years old with ≥ 80 NKG2DL Letter reSeArCH pNKCs or with NKG2D-blocked pNKCs (Fig. 2d) . When transplanted at identical numbers into NSG mice, AML cells from cultures with unblocked pNKCs engrafted 10 ± 1.5 weeks faster and reduced mouse survival (Fig. 2e, f, Extended Data Fig. 6e, f) . These data show that NKG2DL + AML cells without LSC activity are preferentially targeted by pNKCs. In co-cultures with NKG2D-blocked pNKCs (or without pNKCs), these NKG2DL + cells dilute NKG2DL − LSCs within the analysed fixed-cell number, and thereby delay engraftment 11 . LSCs also display reduced expression of ligands (CD112 and CD155) for the activating NK receptor DNAM-1, of the co-stimulatory molecules CD80 and CD86, and of HLA-ABC 12 (Extended Data Fig. 6g, h ). Co-culture with pNKCs selectively reduced CD155
+ and CD112 + subpopulations of AML cells (Extended Data Fig. 6i, j) , as observed for NKG2DL + cells (Fig. 2b , c, Extended Data Fig. 6a ). Finally, gene-set enrichment analysis (GSEA) revealed the depletion of immune and inflammatory response-associated gene signatures in LSCs (Extended Data Fig. 6k, l) . Together, these results demonstrate that LSCs are immuneprivileged (as they evade killing by NK cells) and indicate that mechanisms beyond the absence of expression of NKG2DLs may contribute to the immune evasion abilities of LSCs.
LSCs reside predominantly within CD34 + subpopulations of AML cells 4 , among which they can be further enriched on the basis of CD38 negativity and other surface markers 13 . LSCs are particularly understudied in the approximately 30% of cases of AML in which CD34 expression is low or absent (termed non-CD34-expressing AML) 14, 15 . We analysed 57 of these cases and observed a heterogeneous intrapatient distribution of NKG2DLs, with overall higher expression levels compared to CD34-expressing AML (Fig. 3a 
CD38
+ or CD34 − (non-stem) subpopulations of AML cells (Fig. 3e-h, Extended Data Fig. 7c, d, j) . Similar associations were observed for GPR56 (ref. 16) and other markers that have previously been reported to enrich LSCs 13 (Extended Data Fig. 7k, l) . In AML samples that display ubiquitous expression of CD34 (Fig. 3i) , being positive for NKG2DLs identified non-clonogenic, non-leukaemogenic CD34 +
NKG2DL
+ cells (Fig. 3j, k) , consistent with the notion that not all CD34 + AML cells are LSCs. By contrast, some cases of AML contained >99% NKG2DL + leukaemic cells (Extended Data Fig. 7b ), and we cannot exclude that NKG2DL + LSCs exist. These data highlight NKG2D-Fc staining as a method to prospectively enrich LSCs in AML, irrespective of whether CD34 is expressed.
Comparison of NKG2DL − and corresponding NKG2DL + subpopulations by gene-expression arrays and RNA sequencing (RNAseq) revealed 22 commonly differentially regulated genes. Among these was the gene that encodes the PARP1 enzyme, which was expressed at higher levels in the NKG2DL − subpopulation (Fig. 4a , Supplementary Tables 3-5). We analysed PARP1 further because of its role in the DNA damage response 17 , a process that is linked to the induction of NKG2DL 18 , and because of its involvement in the regulation of apoptosis, senescence, the cell cycle and differentiation in AML cells [19] [20] [21] . Moreover, we found that the high expression of PARP1 was associated with poor outcome in patients with AML (Extended Data Fig. 8a) .
Immunoblotting confirmed increased expression of the PARP1 protein in NKG2DL
− and CD34 + subpopulations of AML cells (Fig. 4b, Extended Data Fig. 8b, c, Supplementary Table 6 ). 
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Genetic or pharmacological inhibition of PARP1 induced expression of NKG2DLs on the surface of CD34 + AML cells, but not healthy haematopoietic stem and progenitor cells (Fig. 4d-g , Extended Data Fig. 8d-l) . PARP1 inhibition specifically promoted the emergence of CD34 + NKG2DL + AML cells in treated bulk-as well as pre-sorted CD34 + (Extended Data Fig. 8j ) or NKG2DL − (Fig. 4f , g, Extended Data Fig. 8l )-AML cells. This apparently did not affect cell viability or in vivo leukaemic burden (Extended Data Fig. 8m-o) . By contrast, other compounds that have previously been reported to induce NKG2DLs 8, 22 , such as retinoic acid, valproic acid or 5-azacytidine, did not promote the emergence of CD34 +
NKG2DL
+ cells (Extended Data  Fig. 9a, b) .
NKG2DLs are regulated both transcriptionally and post-transcriptionally (for example, by shedding from the cell surface 23 ). We did not observe a difference in release of NKG2DLs between CD34
+ LSCenriched cells and corresponding CD34
− non-LSCs (Extended Data Fig. 9c ), but NKG2DL + AML cells showed higher levels of expression of NKG2DL mRNAs than NKG2DL − counterparts (Extended Data Fig. 9d , e). Treatment with small interfering (si) RNAs targeting PARP1, or treatment with the PARP1 inhibitor AG-14361, robustly induced NKG2DL transcripts between 6-and more than 50-fold (Fig. 4h , Extended Data Fig. 9f, g ). PARP1-binding sites were identified by in silico analysis in NKG2DL promoters ( Supplementary Fig. 5 ), and binding was confirmed by chromatin immunoprecipitation (Fig. 4i) . Together, these data suggest that increased expression of PARP1 in LSCs selectively represses transcription of NKG2DLs, which can be reverted by PARP inhibition.
When AML cells pre-treated with AG-14361 were injected into NSG mice that were co-transplanted with pNKCs, a considerable reduction of leukaemic cell burden was observed compared to control settings (Extended Data Fig. 10a ), which indicates that PARP inhibition sensitizes AML cells to control by NK cells in vivo. Consistently, the in vivo treatment of NSG mice transplanted with human AML cells with AG-14361, followed by administration of pNKCs, inhibited long-term in vivo leukaemogenesis, which was not observed in mice that were treated with the PARP1 inhibitor or with pNKCs alone (Fig. 4j, Extended Data Fig. 10b) . Notably, the anti-leukaemic effect of the co-treatment was abrogated by NKG2D blockade (AG-14361 combined with blocked pNKCs), which demonstrates that the combination of PARP inhibition and control by NK cells mediates synergistic anti-leukaemic effects that involve induction of NKG2DLs.
Our studies provide molecular, cellular and functional in vivo evidence that LSC activity is linked to immune evasion. The absence of expression of NKG2DLs may constitute a universal LSC marker, because it takes advantage of a general functional property of LSCsnamely, their capacity to evade immune surveillance by NK cells. The selective suppression of NKG2DLs on LSCs may reflect a resemblance to their cells of origin (healthy haematopoietic stem and progenitor cells), which also maintain these ligands in a repressed state (Extended Data Fig. 10c-g ). Stemness-associated immune evasion in AML probably involves mechanisms beyond NKG2D (Extended Data Fig. 6k , l) and possibly extends to other forms of cancer [24] [25] [26] [27] . Our finding that PARP1 inhibition installs NKG2DLs on the surface of LSCs is of particular interest because PARP1 inhibitors are well-tolerated, not only in our experimental model (Extended Data Fig. 10h -j) but also in patients with cancer 28, 29 . At advanced stages of cancer, immune surveillance is disturbed by multiple mechanisms beyond those that affect the expression of NKG2DLs 30 . Thus, the immune-sensitizing effect of PARP inhibition on LSCs may be particularly exploitable when applied in the context of a functionally restored immune system (for example, at minimal residual disease stage and/ or in settings with immune stimulatory drugs, allogeneic stem-cell transplant or NK cell therapies), in which combinatorial treatment may allow for the specific targeting of LSCs with the aim of achieving an immune-mediated, long-term cure for AML.
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MEthodS
Primary AML cells and samples of healthy donors. Peripheral blood or bone marrow samples were obtained at diagnosis from patients with AML after informed consent in accordance with the Helsinki protocol. For the correlations with clinical and molecular characteristics shown in Fig. 1p, Extended Data Fig. 3 , all patients admitted to the University Hospital Tuebingen between 2005 and 2017 who agreed to participate in the study after informed consent were included, if technically feasible. Patient samples were anonymized by the principal investigators (C. Lengerke, H.R.S. and A.T.) using continuous case numbers. Human cord blood samples of healthy newborn babies of both sexes were collected at the University Hospital Basel upon availability. All relevant ethical regulations were taken into account and the study was conducted according to the guidelines of the local ethics committees (vote 13/2007V, S-112/2010 and EKNZ2015/335). Cells were processed by density gradient centrifugation, viably frozen and freshly thawed for each experiment 11 . Flow cytometry. Human cells. Fluorescence conjugates targeting human CD33, CD34, CD38, CD133, CD117, CD45, CD44, CD123, CD99, CD96, CD25, TIM3, PD-L1 (BD Biosciences), CD14, CD13 (eBiosciences), CD3, GPR56, CD19, CD80, CD86, CD112, CD155 (Biolegend) and B7-H6 (R&D) were used. For specific NKG2DL stainings, human MICA, MICB, ULBP1 and ULBP2, ULBP5 or ULBP6 antibodies were used as previously described 10 . NKG2D-Fc or corresponding isotype control (R&D) were biotinylated using one-step biotinylation kit (MACS Miltenyi) according to the manufacturer's instructions and-after blocking of cells with human IgG (Sigma Aldrich)-detected with streptavidin-PE (Life Technologies) as secondary reagent. In some cases, binding of NKG2D-Fc was detected by PE-anti-human IgG1 (SouthernBiotech). SytoxBlue or 7-AAD was used for live-and dead-cell discrimination. Gating strategies can be found in Supplementary Fig. 2 . Mouse cells. Expression of NKG2DLs was determined using FITC-labelled mouse NKG2D tetramers with HLA-A * 0201 as control tetramer, as previously described 31 . Haematopoietic stem cells and progenitors were identified as previously described, and antibodies against lineage cocktail (Biolegend), Ly6A/E (SCA-1), CD117 (KIT), CD48, CD150, CD16/32 (all Biolegend) and CD34 (eBiosciences) were used 32 . Flow cytometric analyses were performed on either a FACS CantoII, LSR II Fortessa (both BD Biosciences) or Cytoflex (Beckman Coulter).
Human and mouse NKG2DL
+ and NKG2DL − subpopulations were isolated by fluorescence-activated cell sorting (FACS) using a FACS Aria III or FACSFusion (BD Biosciences). CD34
+ and CD34 − cell cellls were isolated by magnetic-activated cell sorting (MACS) (Miltenyi). Post-sort purity was routinely >95%. Table 2 ; both female and male mice were used as available). In samples with <95% blast count, AML cells were used after enrichment by FACS or MACS using pan-leukaemic antigens or CD3 depletion. Engraftment was monitored as previously described 11 and defined as ≥1% human leukaemic cells in mouse peripheral blood or bone marrow, as assessed by multi-colour flow cytometry using antibodies against human leukaemic antigens. All mice underwent final bone marrow, peripheral blood and organ assessment by multi-colour flow cytometry. Whole-body histopathology with H&E and anti-human-CD33 (Ventana, mouse monoclonal, clone QBEnd 10, RTU) and CD34 (Ventana, mouse monoclonal, clone QBEnd 10, RTU) antibody staining was performed to verify engraftment. Homing assays were performed as described 11 using sorted CFSE (CellTrace CFSE Cell Proliferation Kit, Thermo Fisher Scientific)-labelled NKG2DL − and NKG2DL + AML cells. To investigate PARP1 inhibition in vivo, NSG mice engrafted with human AML cells or healthy BALB/c mice were injected intraperitoneally with 10 mg/kg AG-14361 or DMSO control for 5 consecutive days as described 38 , and pNKCs were transplanted 24 h later if indicated. For in vivo analysis of chemotherapy resistance, NSG mice engrafted with human AML cells were treated with 1 mg/day cytarabine (Cytostar, Pfizer) for 2 to 4 consecutive days via subcutaneous injections; leukaemic infiltration and expression of NKG2DLs were measured in cells by analysing bone marrow cells collected before (by intrafemoral punction) and 48 h after completion of cytarabine treatment. For experiments with syngeneic leukaemic models, sorted NKG2DL − or NKG2DL + Ly5.2 cells isolated from the bone marrow (Mll-Enl) 33 or spleen (Mll-ptd/Flt3-ITD) 34 of leukaemic mice were transplanted (1 × 10 5 cells per mouse for primary assays, and 5 × 10 4 cells per mouse for secondary assays) via the tail vein into sublethally irradiated Ly5.1 mice pre-treated or not with InVivoMAb anti-mouse NK1.1 antibody (BioXcell, West-Lebanon, 250 μg every 8-10 days, intraperitoneal injection). Mice were euthanized at signs of disease such as splenomegaly, weight loss or apathy, and analysed for spleen size and weight, bone marrow Ly5.2 donor chimerism, blood counts (Advia120 Hematology Analyzer, Multispecies version 5.9.0-MS software, Bayer) and whole-body histopathology. May-Grünwald-Giemsa staining and colony-formation assays. Sorted NKG2DL − and NKG2DL + cells were analysed by May-Grünwald staining according to standard procedures, and scored in colony-forming unit methylcellulose assays (human, Methocult H4434, StemCell Technologies; mouse, Methocult M3434, StemCell Technologies) according to the manufacturer's protocol. In vitro treatments of primary human AML and cord blood cells, and apoptosis assays. Primary human AML cells were cultured in RPMI1640 supplemented with 10% FCS and cord blood cells in X-Vivo 20 (Lonza) supplemented with 100 ng/ml SCF, 100 ng/ml TPO, 100 ng/ml Flt3-L and 60 ng/ml IL-3 (all Peprotech). AG-14361 (20 μM, Selleckchem), DMSO (0.2%), veliparib (10 μM, Selleckchem), azacytidine (5 μM, Sigma-Aldrich), all-trans retinoic acid (ATRA, 1 μM, Sigma-Aldrich), valproic acid (VPA, 2 μM, Sigma-Aldrich), or NKG2D-Fc or isotype control (10 μg/ml) (AML cells, 24 h; cord blood cells, 48 h) was added. Transfection with individual or scrambled PARP1, or with scrambled non-coding control Silencer Select, siRNAs (Life Technologies) using Lipofectamine RNAiMAX reagent (Life Technologies) was perfomed. The following siRNAs were used: s1097 sense: GGUGAUCGGUAGCAACAAATT; antisense: UUUGUUGCUACCGAUCACCGT; s1098 sense: CCAUCGAUGUCA ACUAUGATT; antisense: UCAUAGUUGACAUCGAUGGGA; s1099 sense: GCA GCUUCAUAACCGAAGATT; antisense: UCUUCGGUUAUGAAGCUGCTT. Annexin V/7-AAD (BD Biosciences, used according to the manufacturer's protocol) was used to distinguish live and apoptotic cells. NK cell assays. pNKCs were generated using K562-41BBL-IL15 feeder cells obtained from St. Jude's Children's Research Hospital as previously described 39 . Mycoplasma tests were regularly performed on the feeder cells. To explore LSC enrichment, AML cells were cultured with or without pNKC for 16 h in the presence or absence of F(ab′) 2 fragments of a blocking anti-NKG2D monoclonal antibody (clone 6H7, provided by Amgen) or isotype control (SouthernBiotech, clone 15H6) (5 μg/ml each) and then retrieved by a ficoll gradient followed by MACS (Miltenyi) selection for leukaemic antigens. After co-culture, CD69 and CD107a expression on NK cells and NKG2DL, CD155 and CD112 expresssion on AML cells were determined by flow cytometry; IFNγ, perforin, granzyme B and TNF levels were analysed by LEGENDplex (Biolegend) according to the manufacturer's instructions; and cytotoxicity of pNKCs determined by 2-h BATDA Europium assays as described 39 . For in vivo analysis, human AML cells were transferred to NSG mice with or without pNKCs. Immunoblot, shedding, chromatin immunoprecipitation, RNA isolation, real-time PCR and targeted next-generation sequencing. Immunoblots were performed according to standard procedures using anti-human-PARP1 (no. 9542S) and anti-β-actin (no. 3700S) or anti-GAPDH (no. 5174P) antibodies and HRP-linked secondary reagents (no. 7074S, anti-rabbit IgG and no. 7076S, anti-mouse IgG, all from Cell Signaling Technology) and quantified by Fiji software. Uncropped images are presented in Supplementary Fig. 1 . Soluble (s) MICA, sMICb, sULBP1 and sULBP2 were analysed in supernatants of sorted AML cells by enzyme-linked immunosorbent assay 10 . Chromatin immunoprecipitation was performed as described 40 using PARP1 antibody (Cell Signaling, no. S9542) and primers (as indicated in Supplementary Table 8 ). Non-immunoprecipitated chromatin was used as input control. For CBFB-MYH11 real-time PCR, RNA was isolated using ZR-Duet DNA/RNA MiniPrep kit (ZymoResearch) and expression was quantified in duplicates on a 7900HT Fast Real-Time PCR System, as well as the expression of ABL1, and calculated as reported 41 . For all other analyses, RNA was isolated using either the Promega ReliaPrep RNA Miniprep Systems (Promega) or the RNeasy Plus Micro Kit (Qiagen) and transcribed into cDNA using the HighCapacity cDNA Archive Kit (Applied Biosystems) or the FastStart Universal SYBR Green Master (ROX) (Roche). The QuantiTect Whole Transcriptome Kit (Qiagen) was used for pre-amplification and reverse transcription of limited amounts of RNA to obtain high yields of cDNA. Gene transcripts were detected using an Applied Biosystems Real-Time PCR 7500 Fast System instrument and Fast Start Universal SYBR Green Master with Rox (Roche) and gene-specific primers. A PBGD (also known as HMBS) control was used for normalization. Fold-change values of gene expression by averages from triplicate measurements were calculated using the ∆∆C T method as described 42 . A list of primers is provided in Supplementary Table 8 . Targeted next-generation sequencing was performed as previously described 11 , using the AML community panel from Thermo Fisher (http://ampliseq.com). Microarray, RNA-seq and GSEA analyses. Microarray gene-expression analyses were performed as previously described 40 . The log 2 -normalized data were linearized and used as input for GSEA (www.broadinstitute.org). One gene-matrix transposed file was generated that contained the transcripts from up-and downregulated genes in the comparison of NKG2DL
− and NKG2DL + blasts (CD34-expressing and non-CD34-expressing AMLs separately), and the transcripts of the Letter reSeArCH LSC signature, the haematopoietic stem cell signature 43 , the progenitor signature and the previously published 17-gene stemness score 44 . GSEA computes whether the gene set is enriched in the generated gene-expression data. For RNA-seq, total RNA from 50,000 cells was isolated using an Arcturus PicoPure RNA isolation kit (Life Technologies, Invitrogen). cDNA libraries were generated with 10 ng of total RNA using the SMARTer Ultra Low RNA kit for Illumina sequencing (Clontech Laboratories) and sequenced with a HiSeq2000 device (Illumina). Sequences were aligned to the hg19 reference genome using the STAR alignment software. DESeq2 45 was used to calculate differentially expressed genes between NKG2DL − and NKG2DL + samples. GSEA was performed using default settings. Biometric analysis of patient datasets. Patient data were analysed using IBM SPSS Statistics v.25. Overall survival was calculated from primary diagnosis until death from any cause. Patients alive at the end of the observation period were censored. Overall survival rates and median survival times were estimated using the Kaplan-Meier method. Data that were not normally distributed were analysed with a Mann-Whitney U test. Kruskal-Wallis tests were used for comparing three independent samples. Differences were considered significant at P values < 0.05. Molecular risk assessment was conducted according to the ELN2017 classification 46 . Analysis of external datasets. RSEM-normalized RNA-seq expression data of 179 primary AML samples from The Cancer Genome Atlas (TCGA) 47 were downloaded from the Broad Institute. Clinical data and mutational status were downloaded from the TCGA website. Samples were stratified according to PARP1 expression (reads per kilobase of transcript per million mapped reads; high, above the median; low, below the median). Survival analysis was performed by using the Mantel-Cox log-rank test in GraphPad Prism 7 software. Statements regarding sample size, randomization and blinding. No statistical methods were used to predetermine sample size. For all in vitro experiments, at least three biological replicates were used or grouped analyses were carried out. For the in vivo experiments, three or more mice per sorted fraction were used unless otherwise indicated; the numbers of injected cells and mice were chosen according to availability of cells (therefore, grouped analyses were carried out). AML samples were chosen according to availability of cellular material and blast percentage (with a preference for samples with higher blast counts). Patients carrying active infections (hepatitis or HIV) were excluded to protect experimenters. Cells from individual AML samples were then distributed to all experimental groups for every sample. Mouse experiments were not randomized. Blinding was not routinely performed. Results including data from blinded experiments are shown in Figs. 1f-h, 3c, d, 4j and Extended Data Fig. 4e -g, j-l. Experiments with blinding have in all cases reproduced the data generated without blinding. Importantly, key experiments were independently replicated by different coauthors and in the three different laboratories. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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All data generated are included in the published Letter and in its Supplementary Information. Gene-expression data that support the findings of this study have been deposited in the Gene Expression Omnibus under accession numbers GSE127200 and 127959. All data are also available from the corresponding author on reasonable request. + cells were sorted either using NKG2D-Fc (n = 65 mice for NKG2DL − ; n = 79 mice for NKG2DL + ; n = 12 cases of AML) or using pooled antibodies against individual NKG2DLs (MICA, MICB, ULBP1 and ULBP2, ULBP5 or ULBP6; n = 3 cases of AML; n = 8 mice per group) and then transplanted at equal numbers for each case of AML intrafemorally in pre-irradiated NSG mice. For detailed mouse numbers per patient and subpopulation, see Supplementary Table 2 .
Human leukaemic engraftment in mouse bone marrow was assessed 12-16 weeks after transplantation; percentages are shown of human leukaemic among mouse bone marrow cells in mice transplanted with NKG2DL − or NKG2DL + subpopulations for each case of AML. Centre values represent means; each dot represents one mouse; a Student's t-test was used for statistical analysis. Note that these samples are also included in the summarized analysis shown in Fig. 1g . e, AML cells with variable expression of NKG2DLs were stained with NKG2D-Fc, isotype or empty control and analysed side-by-side without prior sorting. f, Quantifications of results obtained in colony formation (left), homing (middle) (n = 3 mice per group and patient sample, except for n = 4 mice in NKG2D-Fc-stained group with patients no. 13 and 76) and in vivo long-term engraftment assays in NSG mice (right). Mice per patient sample and condition: no. 110, 3 NKG2D-Fc, 3 isotype and 2 empty control; no. 76, 2 NKG2D-Fc, 2 isotype and 2 empty control; no. 13, 3 NKG2D-Fc, 3 isotype and 2 empty control; and no. 72, 4 NKG2D-Fc, 4 isotype and 3 empty control. g, Annexin V and 7-AAD stainings indicating apoptotic (left) and live (right) cells among AML cells incubated for 24 h with NKG2D-Fc, isotype or control medium (n = 10 cases of AML). f, Two-sided Kruskal-Wallis test was used for statistical analysis. Centre values represent mean, error bars represent s.d. Fig. 3 | Association between surface expression of NKG2DLs and molecular and clinical parameters in patients with AML. a, Cells from patients with known genetic and molecular profiles were stained with conjugated NKG2D-Fc chimeric protein and included in the analyses. Numbers of patients with positive or negative results for the respective mutation are shown below each analysis; patients with an unknown result for the particular analysis are not shown. Note that cases of AML that belong to the favourable molecular European LeukaemiaNet (ELN) risk group or with detectable inv(16) showed higher expression of NKG2DLs when compared to AML of other risk groups or without inv (16) . For statistical analyses, a Kruskal-Wallis test was used for karyotype and ELN 2017 risk group, and a Mann-Whitney U test for all other data. b-e, Surface expression of NKG2DLs assessed at diagnosis (b) was compared between patients who achieved or did not achieve complete remission (CR) or complete remission with incomplete haematologic recovery (CRi) after induction chemotherapy (c), as well as between those patients who-after achieving complete remission (both with and without incomplete haematologic recovery)-did or did not experience subsequent relapse (d). Patients with initial high percentages of NKG2DL + cells among total AML cells more often achieve-and, by trend, also sustainremission. A Mann-Whitney U test was used for statistical analysis. a, c, d, Boxes indicate the median and interquartile range, and whiskers represent data up to 1.5 × the interquartile range; outliers that range from 1.5-3 × the interquartile range are depicted as circles. In e, patients with high (n = 75) versus low (n = 75) expression of NKG2DLs (left), and patients with ≥80% NKG2DL + (n = 24) versus ≥ 80% NKG2DL − (n = 56) cells among total AML cells (right) were compared with respect to overall survival. Note that when only patients younger than 65 years are included, improved survival is observed in cases with ≥80% NKG2DL + compared to ≥80% NKG2DL − cells among total AML cells (as shown in Fig. 1p ). For survival analyses, the log-rank (Mantel-Cox) test was used for statistical analyses. For all other tests, two-sided statistical tests were used. Fig. 4 | Expression of NKG2DLs on mouse leukaemic cells and association with a lack of leukaemogenicity in syngeneic mouse models. a, b, Staining of whole bone marrow cells derived from healthy wild-type (WT), pre-leukaemic (chromatin immunoprecipitation, Dnmt3a or Tet2 mutated) or leukaemic (Mll-Enl, Mll-ptd/Flt3-ITD and Mll-Af9) mice using a mouse NKG2D tetramer. Representative flow cytometric plots (a) and summarized quantifications of NKG2DL + cells among total mouse bone marrow cells (b) (n = 3 mice per model and condition; a two-sided Student's t-test was used for statistical analysis). c-m, NKG2DL
Extended Data
− and corresponding NKG2DL + cells were sorted from leukaemic Mll-Enl and Mll-ptd/Flt3-ITD mice and analysed by qRT-PCR for the genetic leukaemic driver (c) (Mll-Enl mice, n = 3), and at equal numbers in colony-forming assays (d) (n = 6 for Mll-Enl mice; n = 3 for Mll-ptd/Flt3-ITD mice). e-n, In vivo primary and secondary transplantation (tx) assays. e, j, Kaplan-Meier-survival analyses (n = 24 mice for primary transplantations; n = 18 mice for secondary transplantations; log-rank Mantel-Cox test was used for statistical analysis). f, k, Spleen assessment with representative images and weight quantification (f, Mll-Enl mice, primary transplantation, n = 9 NKG2DL − and n = 12 NKG2DL + ; secondary transplantation, n = 10 NKG2DL − and n = 12 NKG2DL + ; k, Mll-ptd/Flt3-ITD mice, primary transplantation, n = 15 NKG2DL − and n = 13 NKG2DL + ; secondary transplantation, n = 9 NKG2DL − and n = 11 NKG2DL + ). g, l, Peripheral blood counts (g, Mll-Enl mice, primary transplantation, n = 6 NKG2DL − and n = 6 NKG2DL + ; secondary transplantation, n = 10 NKG2DL − and n = 9 NKG2DL + ; l, Mll-ptd/Flt3-ITD mice, primary transplantation, n = 14 NKG2DL − and n = 12 NKG2DL + ; secondary transplantation, n = 11 NKG2DL − and n = 11 NKG2DL + ). RBCs, red blood cells; WBCs, white blood cells. h, m, i, n, Representative histopathological analyses: spleen (h, m), bone marrow (i, n). H&E. Scale bars, 50 μm. A two-sided Mann-Whitney U test (g, l, WBCs, primary transplantation; g, platelets, secondary transplantation) or a two-sided Student's t-test (all other analyses) were used for statistical analysis. Centre values represent mean, error bars represent s.d. for all plots. + and CD34 − subpopulations of CD34-expressing cases of AML (n = 33) (j). In some cases the sum of the percentage of positive cells exceeds 100%, which reflects the fact that individual AML cells can express more than one NKG2DL. A two-sided Mann-Whitney U test was used for statistical analysis. k, l, Co-staining of NKG2DLs and LSC markers in CD33
+ AML cells (k, n = 9 cases of AML, of which 9 out of 9 cases expressed GPR56 and CD133, and only 3 out of 9 cases expressed CD96) and within CD34 + CD38 − subpopulations of AML cells (l, n = 5 cases of AML; notably, in the other 7 cases of AML we analysed, all CD34 + CD38 − cells were found to lack expression of NKG2DLs). A two-sided Student's t-test was used in k, l. Centre values represent mean, error bars represent s.d. 6 AML cells per mouse), which afterwards were co-transplanted (or not) with pNKCs (1.5 × 10 7 pNKCs per mouse) (n = 3 mice per condition and patient, n = 5 cases of AML). Mice were analysed for the presence of leukaemic cells in bone marrow, peripheral blood, liver and spleen at 16 h after transplantation. Summarized results of n = 5 independent biological experiments are shown, after normalization to 'DMSO control without NK cells' (which was set to 1). Statistical analysis was performed using a two-sided Mann-Whitney U test. b, In vivo treatment: mice transplanted with human AML cells (no. 35, 1.5 × 10 6 AML cells per mouse, transplanted intrafemorally, n = 6 mice per group) were treated with AG-14361 (10 mg kg -1 intraperitoneally, on days 1 to 5 after transplantation) or DMSO control, and afterwards co-transplanted (or not) with pNKCs (4.5 × 10 6 pNKCs per mouse administered once intravenously on day 6 after transplantation, pre-treated or not with anti-NKG2D or isotype control, 5 μg ml -1 ). Mice were analysed at week nine after transplantation for leukaemic engraftment. Note that between day 6 after transplantation and the final analysis time point, no further treatment was applied. See schematic of the experiment and further data with higher (10:1) pNKC:AML cell ratio in Fig. 4j nature research | reporting summary
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For biometrical analyses, patient data were analyzed using IBM SPSS Statistics (version 25, IBM).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
All data shown in this study will be deposited in Gene Expression Omnibus prior to publication. All other relevant data are available from the corresponding author upon request.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample size. For all in vitro experiments, at least three biological replicates were used or grouped analyses were carried out. For the in vivo experiments three or more mice per sorted fraction were used unless otherwise indicated; the number of injected cells and mice were chosen according to availability of cells therefore grouped analyses were carried out.
Data exclusions No technically sound data were excluded from the analyses, except when technical issues were encountered, such as:
-lot-dependent unspecific binding of the secondary antibody for Fc chimera protein leading to failure to correctly separate NKG2DLneg from NKG2DLpos AML cells (affected experiments: 4 experiments prepared to generate data as presented in Fig. 1g ) -lack of engraftment of any human cell population, due to transplantation to NSG mice that due to unknown circumstances were not anymore immune suppressed (identified in each transplanted animal to carry, among others, mouse B-cells); affected experiments: 8 experiments prepared as additional replicate data to the results presented in Fig. 2e-f ).
-one experiment aimed to replicate the results in Figure 4c and Extended Data Figure 8d ) with additional two AML patient samples showed for unknown reasons very low cell viability after culture, including the vehicle control, and was therefore excluded from the analysis.
-one experiment aimed to replicate the results in Fig. 4e with additional five AML patient samples showed for unknown reasons very low cell viability after culture in all conditions including the vehicle control and was therefore excluded from analysis. -in Figure 4j , two experiments were excluded due to retrospectively confirmed T-cell contamination in the injected pNKCs. For FACS experiments, Propidium iodide, DAPI, or 7-AAD and/or physical parameters were used to exclude dead cells.
Replication
All attempts at replication, that did not encounter technical issues during the experiment, reliably reproduced the presented data sets. For all experiments, at least three biological replicates were performed. Additionally, some of the biological replicates were furthermore each performed in technical replicates.
Randomization AML samples were chosen according to availability of cellular material and blast percentage (with a preference for samples with higher blast counts). Patients carrying active infections (hepatitis, HIV) were excluded to protect experimentators. Cells from individual AML samples were then distributed to all experimental groups for every sample. Mouse experiments were not randomised.
Blinding
Blinding was not routinely performed. Results including data from blinded experiments are shown in Fig. 1f-h, Fig. 3c-d, Fig. 4j and Extended Data Fig. 4e -g and j-l. Experiments with blinding have in all cases reproduced the data generated without blinding. Importantly, key experiments were independently replicated by different co-authors and in the three different involved laboratories.
Reporting for specific materials, systems and methods nature research | reporting summary
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Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Peripheral blood from AML patients was collected and prepared as described in the Supplemental Methods Section. In brief, PBMCs were purified upon a Ficoll gradient followed by a lysis of remaining erythrocytes. Cells were counted, frozen in RPMI1640 supplemented with 20% FCS and 10% DMSO at a density of 10x10^6 or 20x10^6 depending of the available cell number and stored in liquid nitrogen. For analysis and sorting, cells were thawed freshly and stained immediately as described in the Supplemental Methods section.
Instrument
Flow cytometry analyses were performed on either a FACS CantoII or LSR II Fortessa (both BD Biosciences) or a BD cytoflex Software BD FACS Diva or CytExpert software were used for data collection. FlowJo versions 10.0.8 or 10.2 were used for data analysis.
Cell population abundance Post-sort purity was always >95% and determined by re-analysis on a FACS Canto II or LSR II Fortessa for sorted populations.
Gating strategy AML cells were identified from patient PBMCs by firstly gating on live cells based on their exclusion of the 7-AAD dye, then on single cells (SSC-H versus SSC-W) followed by gating on a forward scatter (FSC)/side scatter (SSC) plot. AML cells were gated on leukemic antigens according to the patient sample's phenotypic information and if applicable NKG2D-Fc chimaera, and by applying corresponding isotype and FMO (Fluorescence minus one) controls.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
